Cool Sense Care Plus

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the prevention of dental cavities.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals are advised to instruct patients to rinse their mouth with 10 to 15 mL of COOLSENSE GARGLE. The gargling should be performed for a duration of 60 seconds before expelling the solution. This method ensures optimal efficacy of the product.

Contraindications

Use is contraindicated in children under 6 years of age due to safety concerns. It is essential to keep this product out of their reach to prevent accidental ingestion or misuse. No other contraindications have been identified.

Warnings and Precautions

It is imperative to adhere to the following warnings and precautions to ensure the safe use of this product.

Warnings Users must discontinue the use of this product and seek consultation from a dentist if any signs of irritation occur. For children under the age of 6, it is crucial to use only a small amount of the product under adult supervision to mitigate the risk of sucking or swallowing. In the event that a child under 6 accidentally swallows a large quantity, immediate medical assistance or consultation with a dentist is necessary. Additionally, this product should be kept out of reach of children under 6 years of age to prevent accidental ingestion.

General Precautions The product must consistently be stored out of the reach of children under 6 years of age to ensure their safety.

No laboratory tests or specific emergency medical help instructions are indicated in the provided information.

Side Effects

Patients should be advised to discontinue use of this product and consult a dentist if any irritation occurs. It is particularly important for caregivers to supervise the use of this product in children under 6 years of age, ensuring that only a small amount is applied to prevent the risk of sucking or swallowing. In the event that a child under 6 accidentally swallows a large amount of the product, immediate medical assistance or consultation with a dentist is recommended.

Additionally, this product should be kept out of reach of children under 6 years of age to minimize the risk of accidental ingestion.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Cool Sense Care Plus (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 6 years of age should use this product only in small amounts and under the supervision of a guardian to prevent sucking or swallowing. In the event that a child in this age group swallows a large quantity, it is imperative to consult a physician or dentist immediately. Additionally, this product must be kept out of the reach of children under 6 years of age to ensure their safety.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients.

It is advisable to monitor elderly patients closely for any potential adverse effects or changes in therapeutic response, given the lack of targeted data for this population. Consideration of individual patient factors, including comorbidities and concurrent medications, is essential in managing treatment effectively in this demographic.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and the need to inform their healthcare provider if they become pregnant or plan to become pregnant while using this medication.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any considerations related to lactation. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In cases of overdosage, immediate medical intervention is crucial, particularly for vulnerable populations such as children. If a child under the age of 6 ingests a significant quantity of the medication, it is imperative to seek medical assistance or consult a dentist without delay.

Healthcare professionals should be aware of the potential symptoms that may arise from an overdosage, although specific symptoms were not detailed in the provided information. It is essential to monitor the patient closely for any adverse effects and to initiate appropriate management procedures based on clinical judgment and established protocols.

In summary, prompt action is necessary in the event of an overdosage, especially in young children, to mitigate potential risks and ensure patient safety.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children under 6 years of age. It is important to emphasize the potential risks associated with accidental ingestion by young children and to encourage patients to store the medication in a secure location.

Storage and Handling

This product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within the recommended temperature range to maintain its efficacy.

Storage conditions must be carefully monitored; the product should not be exposed to high or low temperatures or direct sunlight. Proper handling and storage are crucial to ensure the integrity and quality of the product throughout its shelf life.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Cool Sense Care Plus, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)